Alpine Immune Sciences, Inc. (ALPN): Price and Financial Metrics


Alpine Immune Sciences, Inc. (ALPN)

Today's Latest Price: $10.92 USD

0.63 (-5.45%)

Updated Jan 27 4:00pm

Add ALPN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 488 in Biotech

See all "A" rated Strong Buy stocks

ALPN Stock Summary

  • ALPN's price/sales ratio is 60.08; that's higher than the P/S ratio of 94.93% of US stocks.
  • Revenue growth over the past 12 months for Alpine Immune Sciences Inc comes in at 434.58%, a number that bests 98.31% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ALPN comes in at -22.33% -- higher than that of merely 11.92% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Alpine Immune Sciences Inc are SRRK, SURF, ARDX, CMRX, and GLYC.
  • ALPN's SEC filings can be seen here. And to visit Alpine Immune Sciences Inc's official web site, go to www.alpineimmunesciences.com.

ALPN Stock Price Chart Interactive Chart >

Price chart for ALPN

ALPN Price/Volume Stats

Current price $10.92 52-week high $16.37
Prev. close $11.55 52-week low $2.05
Day low $10.84 Volume 153,600
Day high $11.55 Avg. volume 121,029
50-day MA $11.89 Dividend yield N/A
200-day MA $8.42 Market Cap 259.93M

Alpine Immune Sciences, Inc. (ALPN) Company Bio


Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.


ALPN Latest News Stream


Event/Time News Detail
Loading, please wait...

ALPN Latest Social Stream


Loading social stream, please wait...

View Full ALPN Social Stream

Latest ALPN News From Around the Web

Below are the latest news stories about Alpine Immune Sciences Inc that investors may wish to consider to help them evaluate ALPN as an investment opportunity.

Alpine Immune Sciences Announces Executive Leadership Addition and Promotion

Alpine Immune Sciences Announces Executive Leadership Addition and Promotion

Yahoo | January 6, 2021

Alpine: Is This A Young Oak Tree?

Know what you own, and know why you own it. - Peter Lynch According to Warren Buffett, being patient and waiting for the right opportunity is the key to successful long-term investing. Resonating with the principle is my investing story with Alpine Immune Sciences (ALPN). As you know, Mr. Buffett...

BioSci Capital Partners on Seeking Alpha | January 5, 2021

Orbimed Advisors Llc Sells 600,000 Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Stock

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Director Orbimed Advisors Llc sold 600,000 shares of the firm’s stock in a transaction that occurred on Monday, December 28th. The shares were sold at an average price of $14.25, for a total transaction of $8,550,000.00. The sale was disclosed in a filing with the SEC, which is available through […]

Watchlist News | January 3, 2021

These 4 Micro-Cap Healthcare Stocks Gained the Most in 2020

If you're like me, you're an eternal optimist when it comes to the march of scientific progress and its ability to improve human life. The stocks that I'll discuss today are micro-cap stocks, which means that they have market capitalizations between $50 million and $300 million. Think of them as early stage public companies that don't have much consistent revenue yet.

Yahoo | January 1, 2021

Orbimed Advisors reduced stake in Alpine Immune Sciences, Inc.

https://www.investing.com/news/stock-market-news/orbimed-advisors-reduced-stake-in-alpine-immune-sciences-inc-2378223

Investing.com | December 31, 2020

Read More 'ALPN' Stories Here

ALPN Price Returns

1-mo -29.27%
3-mo 42.19%
6-mo -5.04%
1-year 276.55%
3-year -2.33%
5-year -41.79%
YTD -13.33%
2020 228.13%
2019 4.35%
2018 -67.14%
2017 25.00%
2016 -71.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.1216 seconds.